Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
Santos
Fabio P S
FP
Rodrigues
Morgani
M
Mac-Donald Bley do Nascimento
Claudia
C
Kerbauy
Fábio R
FR
Ribeiro
Andreza Alice Feitosa
AA
Mauro Kutner
José
J
Hamerschlak
Nelson
N
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides; D001752:Blast Crisis / Q000139:chemically induced / Q000276:immunology / Q000503:physiopathology; D000069439:Dasatinib; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007049:Iatrogenic Disease / Q000517:prevention & control; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000139:chemically induced* / Q000276:immunology / Q000503:physiopathology; D011241:Prednisone / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D012074:Remission Induction / Q000379:methods; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D007166:Immunosuppressive Agents; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; C498826:nilotinib; D000069439:Dasatinib; D011241:Prednisone